Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Israeli scientist Michael Yartsev, PhD, CV Starr postdoctoral research fellow of the Princeton Neuroscience Institute at Princeton University, won the 2013 Eppendorf & Science Prize for Neurobiology. Dr. Yartsev uses an unusual animal model—the bat—to study the underlying neural mechanisms of spatial memory and navigation in the mammalian brain.
March 2014—The Center for Phlebotomy Education will conduct intensive three-day seminars in Indianapolis and San Francisco for those who train or manage phlebotomists. The event will provide strategies to help attendees reduce expenses by cultivating satisfied, long-term employees; cut costs through process improvement; nurture professionalism and responsibility among specimen-collection personnel; implement different learning styles to maximize teaching; and mentor students and new staff.
Definiens received the 2013 Global Frost & Sullivan Award for Company of the Year for Global Tissue Diagnostics and Pathology Imaging Solutions.
March 2014—Promega launched the QuantiFluor One dsDNA System, a sensitive, dsDNA-specific fluorescent dye for use in research and clinical workflows. The dye system is integrated into the Promega Quantus Fluorometer and GloMax detection instruments but is compatible with any fluorometer capable of measuring the appropriate fluorescence excitation and emission spectra.
March 2014—The Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, New York City, have adopted Qiagen’s Ingenuity Variant Analysis solution for research and translational genomics applications related to characterizing and identifying rare diseases.
March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.
March 2014—Bio SB launched the Normal Human Tissue Micro Array and the Infectious Disease Cell Line Micro Array. The NH-TMA arrays are available in 11- or 23-core configurations, allowing testing of multiple tissues on one slide, and are validated for use with more than 100 antibodies in immunohistochemistry.
March 2014—Terumo BCT released Quantum Software 2.0, updated and enhanced software for the Quantum Cell Expansion System, as part of its ongoing goal to aid cell-therapy companies and research organizations in current Good Manufacturing Practices and in compliance with part 11 of the Code of Federal Regulations.
February 2014—Applied Spectral Imaging (ASI) and Biocare Medical signed a partnership agreement in which Biocare will distribute ASI’s IHC and CISH imaging and analysis solution, GenASIs Pathology, in the United States. The agreement brings to cytopathology and anatomic pathology laboratories a fully integrated solution that improves quality while providing workflow efficiencies.
February 2014—Telcor’s QML point-of-care software solution now provides connectivity for the Sofia fluorescent immunoassay analyzer.
